Press release
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
- One Oral and Four Poster Presentations Highlight Seralutinib’s Potential Across Pulmonary Hypertension and Fibrotic Lung Disease - SAN DIEGO--(BUSINESS
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"\n- One Oral and Four Poster Presentations Highlight Seralutinib’s Potential Across Pulmonary Hypertension and Fibrotic Lung Disease -\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will be presented at the European Respiratory Society (ERS) Congress 2025, which takes place from September 27th through October 1st in Amsterdam, Netherlands and online. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.\n\n\nERS 2025 Presentation Details:\n\n\nSession Type: Oral Presentation\nSession Title: From omics to targets: emerging insights into chronic pulmonary disease mechanisms (Session 94)\nSession Date & Time: September 28th, 9:30am – 10:45am CEST\nLocation: Amtrium\nAbstract Number: OA1201\nPresentation Title: Seralutinib targets fibrotic pathways in IPF: Evidence from single‑cell transcriptomics\nPresenter: Dr. Rui Benfeitas (Chiesi Group)\n\n\nSession Type: Poster Presentation\nSession Title: Preclinical insights into rare diseases (Session 75)\nSession Date & Time: September 28th, 8:00am – 9:30am CEST\nLocation: PS-7\nAbstract Number: PA1039\nPresentation Title: Seralutinib demonstrates in vitro reduction of vascular inflammatory drivers underlying pulmonary hypertension\nPresenter: Dr. Zhaoqing Ding (Gossamer Bio)\n\n\nSession Type: Poster Presentation\nSession Title: Translational studies in interstitial lung disease of known causes (Session 149)\nSession Date & Time: September 28th, 12:30pm – 2:00pm CEST\nLocation: PS-34\nAbstract Number: PA1864\nPresentation Title: Seralutinib shows significant anti-fibrotic effects: Evidence from patient-derived models\nPresenter: Dr. Ravikumar Sitapara (Gossamer Bio)\n\n\nSession Type: Poster Presentation\nSession Title: Pulmonary arterial hypertension: risk assessment and impact of current and newly developed treatments (Session 423)\nSession Date & Time: September 30th, 8:00am – 9:30am CEST\nLocation: PS-38\nAbstract Number: PA5143\nPresentation Title: Seralutinib increases small pulmonary artery ...